Supernus Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Supernus Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Supernus Pharmaceuticals generated -$4.8 million of operating cash flow and spent $568,000 on capital expenditures. That left free cash flow of -$5.4 million, a free-cash-flow margin of -2.5% of revenue. Free cash flow was down 109.3% from the prior year's $58.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Supernus Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -58.37M | -2.29M | -4.11M | -45.12M | 22.50M | -11.83M | 15.33M | 38.50M | 19.92M | 124.00K | 1.18M | -15.98M |
| Net Income growth (YoY) | -359.44% | — | -126.78% | -217.20% | +12.97% | -9637.90% | +1204.51% | — | — | -99.27% | -95.39% | -1013.44% |
| Depreciation & Amortization | 25.75M | 26.13M | 25.02M | 24.81M | 21.36M | 20.38M | 18.84M | 20.10M | 20.72M | 20.75M | 21.68M | 21.86M |
| Stock-Based Compensation | 8.64M | 8.48M | 9.65M | 7.83M | 7.51M | 8.07M | 7.63M | 7.67M | 6.55M | 5.90M | 6.45M | 7.92M |
| Change in Working Capital | -11.91M | -6.87M | -28.00M | -52.74M | 709.00K | 12.48M | -4.71M | -1.89M | -10.80M | 913.00K | 10.17M | 16.02M |
| Operating Cash Flow | -4.81M | 66.52M | 19.86M | -61.66M | 58.53M | 30.60M | 44.41M | 53.52M | 35.62M | 38.40M | 44.96M | 35.88M |
| Capital Expenditures | -568.00K | 0 | -427.00K | -129.00K | -455.00K | -327.00K | -213.00K | -200.00K | -64.00K | -248.00K | 36.00K | -150.00K |
| Investing Cash Flow | 7.09M | -19.22M | -51.31M | 48.71M | -30.61M | 37.32M | -12.64M | -77.01M | -48.59M | -51.62M | -65.98M | 34.63M |
| Financing Cash Flow | -7.20M | 9.12M | 8.53M | 21.07M | 935.00K | -21.40M | 5.89M | 3.08M | 1.66M | 1.57M | 1.09M | -230.00K |
| Net Change in Cash | -4.92M | 56.42M | -22.92M | 8.11M | 28.86M | 46.52M | 37.66M | -20.42M | -11.31M | -11.65M | -19.93M | 70.28M |
| Free Cash Flow | -5.38M | 66.52M | 19.43M | -61.79M | 58.08M | 30.27M | 44.19M | 53.32M | 35.56M | 38.15M | 44.99M | 35.73M |
This table shows 12 quarterly periods of Supernus Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SUPN's reporting calendar. What is a cash flow statement?